Strategies implemented to increase HPV vaccine uptake and confidence among men who have sex with men and transgender people: A systematic review Authors: Helena Avermark, Sofia Tzirita, Erik Radix, Sunjuri Sun, Sibylle Herzig van Wees Published: 2026 ABSTRACT ABSTRACTMen who have sex with men (MSM) and transgender persons are disproportionately affected by HPV-related disease. The HPV vaccine effectively prevents infection, but vaccine uptake remains suboptimal in this group. Thus, this systematic review aimed to synthesize the literature on interventions and strategies implemented to increase HPV vaccine confidence and uptake among MSM and transgender persons. Six databases were searched in May 2025. We assessed risk of bias and extracted and descriptively summarized key data through narrative synthesis and content analysis. Sixteen articles reporting on eight interventions were identified, all implemented in high-income settings. The interventions can be broadly categorized into two types: strategies to integrate HPV vaccination into existing health services and digital interventions aimed at generating vaccine demand. Overall, evidence remains limited on interventions to increase HPV vaccine uptake in these groups, particularly studies focusing on the needs of transgender persons. Background The Human Papillomavirus (HPV) is a common sexually transmitted infection globally, with most sexually active individuals contracting the virus at some point in their lives if not vaccinated.1 In some cases, persistent infections can lead to various forms of cancer. While HPV is most widely known for its role in the development of cervical cancer, it is also responsible for around 87% of anal cancer cases, a notable proportion of genital cancers, and nearly all cases of oropharyngeal cancer, contributing to considerable health burdens across all genders.2,3 There is growing evidence demonstrating that HPV vaccination can effectively lower the risk of HPV-related cancer among men.4,5 Men who have sex with men (MSM), transgender and gender-diverse persons are disproportionately affected, with higher prevalence of persistent HPV infections and up to 20 times greater incidence of HPV-related anal cancer compared with men who have sex with women (MSW).6–8 Nevertheless, structured HPV vaccination efforts have largely focused on cervical cancer prevention and, consequently, primarily targeted girls and women. The lack of structured efforts to promote uptake among men has resulted in low HPV vaccine uptake among boys and men,9 including in groups at high risk of HPV-related diseases, such as MSM and transgender people.10 While there is evidence to suggest that MSW benefit from some indirect protection in settings with relatively high HPV vaccine uptake among women,11 this does not necessarily extend to MSM and transgender people. This leaves these individuals unprotected. Furthermore, it has been suggested that gender-neutral programs could enhance overall HPV vaccine confidence,12 promote gender equality13 and accelerate the elimination of HPV-related cancers.14 Consequently, an increasing number of countries are shifting toward implementing gender-neutral vaccination programs, particularly for boys through school-based vaccination programs.15 In parallel, targeted HPV vaccination and catch-up programs for MSM and other persons at higher risk have been the subject of increasing academic interest. Health economic evaluations have shown targeted catch-up vaccination for young MSM and transgender people to be cost-effective and improve health outcomes, also in settings where all adolescents are routinely offered the vaccine.16–19 Previous reviews have focused on HPV vaccine perceptions20 and experiences,21 vaccine uptake9,10 and series completion9 among MSM, men living with HIV and transgender people. While they generally describe low risk-perception and limited knowledge of HPV-related diseases as prominent barriers to HPV vaccination among MSM and transgender people, structural barriers and the influence of political and socio-cultural context are also highlighted alongside the need for tailored approaches to reach these groups.9,10,21 Taken together, the described barriers can be conceptualized using the World Health Organization’s Behavioral and Social Drivers (BeSD) of vaccination framework, which positions vaccination as influenced by four interrelated domains: thinking and feeling (e.g., vaccine knowledge and confidence, risk perception), social processes (e.g., norms and trust), motivation to vaccinate, and practical issues related to access and service delivery.22 Nevertheless, a notable gap exists in the literature regarding efforts to increase HPV vaccine confidence and uptake among MSM and transgender people. Such a review can inform evidence-based public health policies and tailored interventions aimed at reducing health disparities related to HPV non-vaccination. Thus, this systematic review aims to synthesize existing literature on interventions aimed at increasing HPV vaccine uptake and confidence among MSM and transgender people. Methods We conducted a systematic literature review based on the following research question: What strategies have been implemented to increase HPV vaccine uptake and confidence among men who have sex with men and transgender people? The review was guided by the Joanna Briggs Institute (JBI) framework for systematic reviews23,24 and reported per the PRISMA 2020 reporting guidelines,25 available in Supplementary file 1. The study protocol was registered in PROSPERO in June 2025 (CRD420251070307). Search strategy A literature search was performed in the following databases: Medline, Embase, Web of Science, PsycINFO, CINAHL and Global Health. A complementary search was done in Google Scholar and the first 200 hits screened. The last search was done 2025–05–27. The search strategy was developed in Medline (Ovid) in collaboration with librarians at the Karolinska Institutet University Library. For each search concept, Medical Subject Headings (MeSH-terms) and free text terms were identified. Some of the key search terms included ‘human papilloma viruses,’ ‘vaccination,’ ‘men who have sex with men’ and ‘transgender people.’ A test search was performed in May 2025. The search was then translated into the other databases. The strategies were peer reviewed by another librarian prior to execution. Databases were searched from inception, without any language restrictions. The full search strategy is available in Supplementary file 2. Study selection All identified records were imported to the software Covidence,26 where a de-duplication was done before the titles and abstracts were screened according to the eligibility criteria. All authors contributed to the screening, so that two authors independently screened each record and a third author resolved conflicts. These steps were repeated for full-text screening. Eligibility criteria We included peer-reviewed qualitative and quantitative primary studies, whether randomized or non-randomized, that focused on interventions or strategies to promote HPV vaccine uptake (understood as receipt of HPV vaccine doses, including HPV vaccine series initiation and completion) and confidence among MSM and transgender people (Table 1). There were no restrictions on settings, geographical location, or language of the report. We excluded previous systematic reviews and meta-analyses, case reports, unpublished reports and study protocols, gray literature, books, editorials, commentaries, and conference abstracts.Table 1.Eligibility criteria. InclusionExclusionPopulationMen who have sex with menGay and bi-sexual menLGBTQ+ menTransgender, intersex and non-binary peopleCis womenCis men having sex with women exclusivelyInterventionInterventions and/or strategies to increase HPV vaccine uptake, confidence, acceptance, awareness and/or knowledgeEfforts integrating the HPV vaccine into existing services or vaccination programsNoneOtherComparatorNot applicableOutcomesHPV vaccine uptakeHPV vaccine confidenceHPV vaccine acceptanceNoneOther Table 1.Eligibility criteria. InclusionExclusionPopulationMen who have sex with menGay and bi-sexual menLGBTQ+ menTransgender, intersex and non-binary peopleCis womenCis men having sex with women exclusivelyInterventionInterventions and/or strategies to increase HPV vaccine uptake, confidence, acceptance, awareness and/or knowledgeEfforts integrating the HPV vaccine into existing services or vaccination programsNoneOtherComparatorNot applicableOutcomesHPV vaccine uptakeHPV vaccine confidenceHPV vaccine acceptanceNoneOther Eligibility criteria. Men who have sex with men Men who have sex with men Gay and bi-sexual men Gay and bi-sexual men LGBTQ+ men LGBTQ+ men Transgender, intersex and non-binary people Transgender, intersex and non-binary people Cis women Cis women Cis men having sex with women exclusively Cis men having sex with women exclusively Interventions and/or strategies to increase HPV vaccine uptake, confidence, acceptance, awareness and/or knowledge Interventions and/or strategies to increase HPV vaccine uptake, confidence, acceptance, awareness and/or knowledge Efforts integrating the HPV vaccine into existing services or vaccination programs Efforts integrating the HPV vaccine into existing services or vaccination programs None None Other Other HPV vaccine uptake HPV vaccine uptake HPV vaccine confidence HPV vaccine confidence HPV vaccine acceptance HPV vaccine acceptance None None Other Other Data extraction and risk of bias assessment Data extraction and risk of bias assessment of each article were conducted in Covidence by two independent authors. Any disagreement, either with data extraction or risk of bias assessment, was resolved in consultation with a third author. We developed a data extraction table (available in Supplementary file 3) guided by our research question and the JBI framework.24 The table was structured to cover, for example, study characteristics (author, publication year, aim) as well as information about the study population and intervention. For risk of bias assessment, we used the JBI critical appraisal tools corresponding to the study design of each article (Supplementary file 4). Risk of bias was not used to exclude studies or to formally weight findings in the synthesis, but to contextualize the findings. Data synthesis and analysis Using our data extraction table as a guide, we performed a synthesis for each extraction element to identify and map key findings. Following PRISMA guidelines, we summarized the study characteristics using descriptive statistics and summary tables. Additionally, we conducted a narrative synthesis of the principal findings, e.g., intervention development and components.27 Additionally, we extracted the lessons learned reported by the authors and synthesized them using content analysis. Throughout this process, all authors met regularly for discussions and feedback. The final synthesis was reviewed and agreed upon by all authors. Certainty assessment The level of evidence and strength of recommendations were assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool28 (Supplementary file 5). This allowed us to classify studies as providing very low, low, moderate, and high-quality evidence and to assess the overall certainty of evidence for key outcomes, rather than individual studies. Given the heterogeneity in study designs, GRADE domains were applied across bodies of evidence per outcome (vaccine initiation and completion). Where multiple articles reported results from the same underlying intervention, these were grouped and assessed as a single body of evidence to avoid double counting and ensure appropriate evaluation. Due to the lack of comparable quantitative outcomes, the GRADE assessment did not include formal meta-analytic estimates but was based on structured qualitative judgment. Results Sixteen articles reporting on eight interventions, of which four were digital interventions and four were intervention strategies integrating HPV vaccination for MSM and transgender people into existing health services, were included in this review (Figure 1). The initial search resulted in 3,721 articles, of which 1,644 remained after de-duplication. The most common reasons for exclusion during full-text screening were related to the report format, e.g., unpublished reports and protocols (n = 10), commentaries or conference abstracts (n = 10) or literature reviews (n = 8). A detailed overview of the individual reports is available in Supplementary file 6. Figure 1.PRISMA flowchart, adapted from page et al.25The flowchart outlines the process of screening studies for the review. It begins with the identification phase, where records from databases and registers total 3,721. These include Embase, Web of Science, MEDLINE, Global Health, CINAHL, Google Scholar and PsycINFO. References removed amount to 2,077, with duplicates identified manually and by Covidence. The screening phase follows, with 1,644 studies screened, leading to 1,579 exclusions. Studies assessed for eligibility number 65, with 49 excluded for reasons such as editorials, protocols, literature reviews, lack of specified intervention, wrong outcomes, wrong target population, grey literature, duplicates and abridged publications. Finally, 16 records are included in the review, describing eight interventions or strategies.A flowchart detailing the screening process of studies for the review, from identification to inclusion. PRISMA flowchart, adapted from page et al.25 Characteristics of the included studies All studies were conducted in high-income settings. Out of the four digital interventions, three were implemented in the United States29–35 and one in China.36 Strategies to integrate HPV vaccination into existing health services were described in Australia,37,38 Canada,39 China40 and the United Kingdom.41–44 All were initiated before the COVID-19 pandemic, the first being the targeted HPV vaccine catch-up program in the United Kingdom (UK) which was piloted across England from 2016 and subsequently scaled to Scotland in 2017.41–44 In addition, although studies were published from 2018 to 2023, it should be highlighted that the data collection for all of them was initiated in or before 2019. All interventions targeted young people, typically defined as aged 18 years29,29,31–36,40 or above. In two cases, the lower age limit was at 16 years of age.38,39 Five papers did not explicitly specify the age of participants.37,41–44 The upper age limit was either 2629–35,37 or 45 36,40–44 years of age. The target group was defined as MSM in all studies, with one study explicitly including both cis gender and transgender men,39 and others restricting participation to cis men only.33–35 The included studies follow a variety of methodological approaches. The majority were randomized controlled trials (RCTs) (n = 6)31–36 and cohort studies (n = 4),37–39,41 followed by two quasi-experimental studies,30,40 one qualitative,29 one observational,44 one cross sectional42 study, and one narrative synthesis.43 The heterogeneity in methodologies was reflected in the variety of reported outcomes. The majority focused on HPV vaccine uptake (including HPV vaccine series initiation or completion).30,32,34,36–42,44 Others assessed outcomes linked to thinking and feeling (e.g. HPV knowledge, HPV vaccine perceptions),31,33 motivational outcomes (e.g., willingness to vaccinate)35,39 or implementation outcomes (e.g. feasibility, acceptability of intervention/service).29,35,42,43 Characteristics of identified interventions and strategies Table 2 provides an overview of the interventions and strategies identified, summarizing their development and components as well as the actors involved.Table 2.Overview of interventions and strategies.TypeIntervention/strategyComponents of InterventionIntervention development and deliveryActors InvolvedDescribed in article(s)Digital interventionUnnamed mHealth educational tool (mobile app) inspired by implementation-intention theoryInformation on HPV, HPV vaccination, insurance enrollment and vaccine costs and sexual health (safe sex practices, condoms, safe sexual toys, STIs and HIV prevention including PrEP and HIV testing), other partnered health centers e.g., social support, housing; and integrated geolocation and directions to MSM-friendly clinics, appointment scheduling and reminders.DevelopmentContent and features were developed using input from an online focus group of 48 ethnically diverse MSM aged 18–26DeliveryDigital messages, instructions, and reminders through a mobile app.Target groupYoung MSMInvolved in ImplementationResearch institutions with support from partner healthcare centersInvolved in RecruitmentMSM dating app popular among racially/ethnically diverse men (for recruitment)Fontenot et al.29Fontenot et al.30 Outsmart HPV, a web-based educational tool inspired by the protection-motivation theoryFour sequential modules with individually tailored content (based on baseline assessment) targeting young MSM, ending with information about the logistics of HPV vaccination, followed by monthly text-based reminders.1.‘‘Learn about HPV” (prevalence, transmission, and related diseases among YGBM)2.‘‘Learn about the Vaccine” (recommendations for YGBM, effectiveness, and individually tailored testimonials on men’s reason of vaccination)3. ‘‘Get Answers” (Q&A barriers and concerns about HPV and HPV vaccination frequently reported by YGBM-tailored to individual’s baseline survey)4. ‘Get Vaccinated,” (logistics of getting the vaccine: available resources, cost, training on how to talk with a provider for the vaccine)-prompted to create individual “Vaccination Plan”DevelopmentContent and design were developed and iteratively updated based on input from group discussions and interviews with young MSM.DeliveryMobile-friendly website with testimonials, infographics, text, and visuals with option to print personalized vaccination plan. Text-based reminders were either automated (unidirectional) or interactive and tailored, incorporating memes, GIFs, and response options.Target groupYoung MSMInvolved in ImplementationResearch institutionsInvolved in RecruitmentSocial media sites (e.g., Facebook, Instagram, Grindr), existing research panels, and university-based health centers and organizations for the recruitmentMcRee et al.31Reiter et al.32Reiter et al.33Reiter et al.34 txt2protect,a text-messaging intervention inspired by the Information, Motivation and Behavior Skills model3-week program covering HPV vaccine information (week 1) (HIV and STIs information, HPV vaccine-safety, efficacy, dosing), vaccine recommendation, how to get the first dose), commonly perceived barriers (week 2) (HPV misinformation, lack of provider recommendation, HPV norms, reason young MSM get vaccinated), and behavioral skills/self-efficacy (week 3) (cost and health insurance, list of clinics offering HPV vaccine, talking with provider/parent about HPV vaccine or sexual identity, vaccination action plan), followed by an eight-month period of motivational messaging to support vaccine uptakeWebsite: information about HPV and contact information for local clinics providing HPV vaccineDevelopmentYoung sexual minority men were engaged in content development (via interviews and surveys), refinement (through an online advisory team), and beta testing.DeliveryText messages (10–12 per day in phase 1, 5–8 per month in phase 2) and a complementary websiteTarget groupYoung sexual minority menInvolved in ImplementationResearch institutionsInvolved in RecruitmentSocial media sites (e.g., Facebook, Instagram, and Twitter), online dating applications for MSM, and a local participant registry for sexual minority individuals interested in translational behavioral researchGerend et al.35 Unnamedweb-based intervention inspired by the Health Belief ModelOnline tutorial (OT): 1.5-min web-based video (peer MSM discussing risks of penile and anal cancers, and genital warts, includes graphic images of genital warts and cancers highlights the effectiveness of HPV vaccination, demonstrates how to receive it at private clinics- video designed to be fully watched without skipping or fast-forwarding2. Self-administered exercise to test their knowledgeOT-MI: OT plus MI via telephoneDevelopmentContents were based on theory-based factors associated with the acceptability of HPV vaccination among local MSM and guided by the Health Belief ModelDelivery5 min web-based video and self-administered exercise (overall 20 min to complete) within 3 days of first log in- up to 5 reminders (in the one-week period), followed by 15 min MITarget groupMSM with no history of HPV vaccine uptakeInvolved in ImplementationResearch institutionsInvolved in RecruitmentExperienced fieldworkers approached prospective MSM in venues frequently visited by local MSM, including gay bars and gay saunas, gave them information sheet, gay websitesWang et al.36Strategies for integration into existing servicesUK Pilot programPiloting an HPV catch-up program by offering free HPV vaccination for MSM ≤ 45 years old through the implementation of a three-dose regimen provided in selected sexual health and HIV clinics (2 doses for <15 years)DeliveryInformation materials for patients and healthcare professionals, e.g., a patient information leaflet, training and clinical guidelines were made available onlineSufficient doses for an equivalent of 100% uptake for dose one, 80% for dose two and 70% for dose three. Each region was responsible for vaccine allocationVaccine could be ordered free of charge through ImmForm (online platform). Clinics could claim £10 (€11.30) per doseTarget GroupMSMInvolved in ImplementationScottish Government initiated the program based on advice from the UK Joint Committee on Vaccination and Immunization, sexual health clinics in UKPollock et al.44Checchi et al.41Edelstein et al.42Forster et al.43 HPV catch-up vaccination for MSM 16–26 years as implemented in Melbourne Sexual Health Clinic, AustraliaState-based, time-limited (30 months) campaign including free HPV vaccination integrated into existing health services; three-dose regimen administered at 0, 1–2, and 12 months.DeliveryHealthcare workers offered HPV vaccination to eligible men attending the Melbourne sexual health clinic.Target GroupMSMInvolved in ImplementationDecided on and funded by the Victorian Government, delivered by sexual health clinics in MelbourneMcGrath et al.37Htaik et al.38 CBO-Private Clinic Service Model Promoting HPV Vaccination among Chinese Men Who Have Sex with MenA five minute educational video with images and a peer MSM describing the consequences of HPV-related cancers, including information on how to get vaccinated (Wang 2021a-modifications: cost of HPV vaccination was updated based on the recent market rate, and information of collaborative clinics (e.g., location and contacts) were added, each participant was sent a discount coupon through SMS/WhatsApp and could enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborative private clinic, five reminders were sent to participants by SMS/WhatsApp at Month 1, 2, 4, 6, and 8)DeliveryMSM, were invited to receive HPV vaccination at gay-friendly private clinicsTarget groupMSM with no history of HPV vaccine uptakeInvolved in ImplementationResearch institutionsInvolved in RecruitmentTrained staff of a CBO providing HIV-related services recruited participants through gay bars or saunas, online, and referrals made by peers and other CBOsWang et al.40 Canadian HPV catch-up vaccination program, soon after initiation of targeted HPV vaccination programsof gay, bisexual, and other men who have sex with men in Canada.A brief written preamble about HPV vaccine and a fact sheet that included information about where to obtain HPV vaccine locallyGBM aged 26 years were eligible for publicly funded HPV vaccinationAge-ineligible individuals either pay out-of- pocket (up to $550 CAD for a full 3-dose series) or seek coverage through medical insuranceDevelopmentCommunity engagement approach: investigators at each site consulted with Community Engagement Committees (staff from local community-based organizations focused on GBM health promotion, including AIDS service organizations, and diverse GBM community members in each city) to guide the content of the questionnaire, recruitment materials, and communication of findings to GBM communitiesDeliveryHPV vaccination to eligible GBMTarget GroupCis- or transgender gay, bisexual, and MSM eligible for publicly funded HPV vaccinationInvolved in ImplementationGovernment of CanadaChambers et al.39 Table 2.Overview of interventions and strategies.TypeIntervention/strategyComponents of InterventionIntervention development and deliveryActors InvolvedDescribed in article(s)Digital interventionUnnamed mHealth educational tool (mobile app) inspired by implementation-intention theoryInformation on HPV, HPV vaccination, insurance enrollment and vaccine costs and sexual health (safe sex practices, condoms, safe sexual toys, STIs and HIV prevention including PrEP and HIV testing), other partnered health centers e.g., social support, housing; and integrated geolocation and directions to MSM-friendly clinics, appointment scheduling and reminders.DevelopmentContent and features were developed using input from an online focus group of 48 ethnically diverse MSM aged 18–26DeliveryDigital messages, instructions, and reminders through a mobile app.Target groupYoung MSMInvolved in ImplementationResearch institutions with support from partner healthcare centersInvolved in RecruitmentMSM dating app popular among racially/ethnically diverse men (for recruitment)Fontenot et al.29Fontenot et al.30 Outsmart HPV, a web-based educational tool inspired by the protection-motivation theoryFour sequential modules with individually tailored content (based on baseline assessment) targeting young MSM, ending with information about the logistics of HPV vaccination, followed by monthly text-based reminders.1.‘‘Learn about HPV” (prevalence, transmission, and related diseases among YGBM)2.‘‘Learn about the Vaccine” (recommendations for YGBM, effectiveness, and individually tailored testimonials on men’s reason of vaccination)3. ‘‘Get Answers” (Q&A barriers and concerns about HPV and HPV vaccination frequently reported by YGBM-tailored to individual’s baseline survey)4. ‘Get Vaccinated,” (logistics of getting the vaccine: available resources, cost, training on how to talk with a provider for the vaccine)-prompted to create individual “Vaccination Plan”DevelopmentContent and design were developed and iteratively updated based on input from group discussions and interviews with young MSM.DeliveryMobile-friendly website with testimonials, infographics, text, and visuals with option to print personalized vaccination plan. Text-based reminders were either automated (unidirectional) or interactive and tailored, incorporating memes, GIFs, and response options.Target groupYoung MSMInvolved in ImplementationResearch institutionsInvolved in RecruitmentSocial media sites (e.g., Facebook, Instagram, Grindr), existing research panels, and university-based health centers and organizations for the recruitmentMcRee et al.31Reiter et al.32Reiter et al.33Reiter et al.34 txt2protect,a text-messaging intervention inspired by the Information, Motivation and Behavior Skills model3-week program covering HPV vaccine information (week 1) (HIV and STIs information, HPV vaccine-safety, efficacy, dosing), vaccine recommendation, how to get the first dose), commonly perceived barriers (week 2) (HPV misinformation, lack of provider recommendation, HPV norms, reason young MSM get vaccinated), and behavioral skills/self-efficacy (week 3) (cost and health insurance, list of clinics offering HPV vaccine, talking with provider/parent about HPV vaccine or sexual identity, vaccination action plan), followed by an eight-month period of motivational messaging to support vaccine uptakeWebsite: information about HPV and contact information for local clinics providing HPV vaccineDevelopmentYoung sexual minority men were engaged in content development (via interviews and surveys), refinement (through an online advisory team), and beta testing.DeliveryText messages (10–12 per day in phase 1, 5–8 per month in phase 2) and a complementary websiteTarget groupYoung sexual minority menInvolved in ImplementationResearch institutionsInvolved in RecruitmentSocial media sites (e.g., Facebook, Instagram, and Twitter), online dating applications for MSM, and a local participant registry for sexual minority individuals interested in translational behavioral researchGerend et al.35 Unnamedweb-based intervention inspired by the Health Belief ModelOnline tutorial (OT): 1.5-min web-based video (peer MSM discussing risks of penile and anal cancers, and genital warts, includes graphic images of genital warts and cancers highlights the effectiveness of HPV vaccination, demonstrates how to receive it at private clinics- video designed to be fully watched without skipping or fast-forwarding2. Self-administered exercise to test their knowledgeOT-MI: OT plus MI via telephoneDevelopmentContents were based on theory-based factors associated with the acceptability of HPV vaccination among local MSM and guided by the Health Belief ModelDelivery5 min web-based video and self-administered exercise (overall 20 min to complete) within 3 days of first log in- up to 5 reminders (in the one-week period), followed by 15 min MITarget groupMSM with no history of HPV vaccine uptakeInvolved in ImplementationResearch institutionsInvolved in RecruitmentExperienced fieldworkers approached prospective MSM in venues frequently visited by local MSM, including gay bars and gay saunas, gave them information sheet, gay websitesWang et al.36Strategies for integration into existing servicesUK Pilot programPiloting an HPV catch-up program by offering free HPV vaccination for MSM ≤ 45 years old through the implementation of a three-dose regimen provided in selected sexual health and HIV clinics (2 doses for <15 years)DeliveryInformation materials for patients and healthcare professionals, e.g., a patient information leaflet, training and clinical guidelines were made available onlineSufficient doses for an equivalent of 100% uptake for dose one, 80% for dose two and 70% for dose three. Each region was responsible for vaccine allocationVaccine could be ordered free of charge through ImmForm (online platform). Clinics could claim £10 (€11.30) per doseTarget GroupMSMInvolved in ImplementationScottish Government initiated the program based on advice from the UK Joint Committee on Vaccination and Immunization, sexual health clinics in UKPollock et al.44Checchi et al.41Edelstein et al.42Forster et al.43 HPV catch-up vaccination for MSM 16–26 years as implemented in Melbourne Sexual Health Clinic, AustraliaState-based, time-limited (30 months) campaign including free HPV vaccination integrated into existing health services; three-dose regimen administered at 0, 1–2, and 12 months.DeliveryHealthcare workers offered HPV vaccination to eligible men attending the Melbourne sexual health clinic.Target GroupMSMInvolved in ImplementationDecided on and funded by the Victorian Government, delivered by sexual health clinics in MelbourneMcGrath et al.37Htaik et al.38 CBO-Private Clinic Service Model Promoting HPV Vaccination among Chinese Men Who Have Sex with MenA five minute educational video with images and a peer MSM describing the consequences of HPV-related cancers, including information on how to get vaccinated (Wang 2021a-modifications: cost of HPV vaccination was updated based on the recent market rate, and information of collaborative clinics (e.g., location and contacts) were added, each participant was sent a discount coupon through SMS/WhatsApp and could enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborative private clinic, five reminders were sent to participants by SMS/WhatsApp at Month 1, 2, 4, 6, and 8)DeliveryMSM, were invited to receive HPV vaccination at gay-friendly private clinicsTarget groupMSM with no history of HPV vaccine uptakeInvolved in ImplementationResearch institutionsInvolved in RecruitmentTrained staff of a CBO providing HIV-related services recruited participants through gay bars or saunas, online, and referrals made by peers and other CBOsWang et al.40 Canadian HPV catch-up vaccination program, soon after initiation of targeted HPV vaccination programsof gay, bisexual, and other men who have sex with men in Canada.A brief written preamble about HPV vaccine and a fact sheet that included information about where to obtain HPV vaccine locallyGBM aged 26 years were eligible for publicly funded HPV vaccinationAge-ineligible individuals either pay out-of- pocket (up to $550 CAD for a full 3-dose series) or seek coverage through medical insuranceDevelopmentCommunity engagement approach: investigators at each site consulted with Community Engagement Committees (staff from local community-based organizations focused on GBM health promotion, including AIDS service organizations, and diverse GBM community members in each city) to guide the content of the questionnaire, recruitment materials, and communication of findings to GBM communitiesDeliveryHPV vaccination to eligible GBMTarget GroupCis- or transgender gay, bisexual, and MSM eligible for publicly funded HPV vaccinationInvolved in ImplementationGovernment of CanadaChambers et al.39 Overview of interventions and strategies. Most of the interventions included a core digital, educational component designed specifically with the objective to reach MSM. This content typically provided essential information on HPV, including prevalence, modes of transmission, and associated health risks.29–36 In addition, it covered important details about HPV vaccination, such as recommended dosing schedules, vaccine effectiveness, and common misconceptions.29–36 Several interventions enriched this content with personal testimonials describing men’s motivations for vaccination or experiences with HPV-related disease, as well as broader sexual health topics such as sexually transmitted infections.29–34 Outsmart HPV31–34 and txt2protect35 tailored this educational content to known barriers faced by MSM, including persistent misinformation about HPV and gaps in provider recommendation. This content was disseminated digitally, through mobile applications,29,30 text messaging programs,35 or web-based platforms.31–34,36,40 Among the interventions embedded within existing services, the UK pilot program41–44 and the Canadian catch-up initiative39 also relied on printed informational leaflets to support HPV vaccine awareness and decision-making. Most of the interventions were multi-component in nature. Beyond educational content, all new interventions included information about local clinics offering HPV vaccination,31–36 while Fontenot et al.’s mobile app extended this further by integrating geolocation and appointment scheduling functionalities.29,30 The same intervention connected users with health centers that provided broader social support, including housing assistance. Furthermore, additional features for building self-efficacy were offered in several interventions, including training on how to initiate conversations with healthcare providers about the HPV vaccine31–35 and prompts urging people to create their own ‘Vaccination Plan.’31–35 Vaccination reminders were also a common feature.29–35 Finally, some interventions had additional external components. The txt2protect established a website with more comprehensive information,35 and Wang et al.36 integrated Motivational Interviewing along with the online tutorial-video offered. Content for the new digital interventions relied on insights from MSM. Researchers conducted focus groups or interviews to create and refine the content to be relevant for them.29–35 Similarly, Chambers et al. 39 followed a community-engagement approach in which investigators collaborated with Community Engagement Committees composed of staff from local LGBTQ organizations and diverse community members. By contrast, Wang et al.36 developed content primarily from theory-driven determinants of HPV vaccine acceptability among MSM, guided by constructs from the Health Belief Model. Notably, there were no reports of transgender people being included in the development processes. Cost considerations were another prominent feature across interventions. All new interventions provided information about vaccine pricing and insurance coverage.29–36 By contrast, interventions integrated within public or sexual health services typically offered the vaccine free of charge to specific age groups. In the UK, subsidized HPV vaccination was available for MSM 45 years or younger,41–44 whereas Australia 37,38 and Canada39 offered subsidized HPV vaccination to MSM aged 16–26. In the case of Canada, individuals outside the target age range could still access vaccination but had to rely on insurance or pay out of pocket.39 Recruitment approaches following the development of the interventions varied across interventions but largely depended on digital platforms. Recruitment strategies implemented after intervention development differed but generally relied on digital platforms. Many studies recruited participants through dating apps,29,30 social media, existing research panels, university health centers, or local community organizations.31–35 However, some relied on trained fieldworkers approaching potential participants in venues frequented by local MSM, including gay bars, saunas, and community websites.36 For system-level programs integrating HPV vaccination into existing services, governmental structures were the main actors involved in the delivery of the vaccine,37,38,41–44 but collaboration between community-based organizations and private practices was also described.40 Findings from content analysis of the lessons learned A content analysis of the lessons learned reported by the authors revealed three overarching themes: 1. Factors leading to increased engagement in initiation and completion of HPV vaccination; 2. Integration of HPV vaccination within preexisting health services; and 3. Structural factors are decisive for HPV vaccination adoption and reach. Factors leading to increased engagement in initiation and completion of HPV vaccination A variety of factors, including the digital and visual designs of interventions, approaches that build self-efficacy and participatory methods used during intervention development, can significantly influence people’s engagement in initiating or completing HPV vaccination. Increased engagement was observed when digital interventions combined online text with visual elements (e.g., infographics, images, videos, and links to additional resources).32,33,35 This effect may be explained by people’s preexisting familiarity with obtaining information digitally,32 improved recall facilitated by visual formats,34 and the sense of safety and anonymity that online platforms provide for discussions related to sexual health.29 Another factor is self-efficacy building, as providing target group-specific information about HPV and HPV vaccination, tailored to attitudes and beliefs and offering practical resources and strategies that build users’ own skills may enhance self-efficacy and increase vaccination intention.31–34 Therefore, there is a need to better map the characteristics of individuals who accept or decline vaccination.41 Implementation intention theory posits that facilitating the formation of concrete action plans supports health behaviors for young people.30 In contexts where stigmatization and marginalization impede HPV vaccine uptake, this approach may prove particularly effective in closing the intention-behavior gap.30,39 An additional element that appeared to strengthen engagement was participatory methods for the intervention development. Such methods can increase the intervention’s relevance and cultural appropriateness34 and crowdsourcing input from both experts and target users can enhance the attractiveness of the content.40 Notably, in the study by Fontenot et al.,29 young people reported enthusiasm about being asked to contribute their perspectives and more than half volunteered to be involved in testing the tool during its development.29 A digital environment can also facilitate the application of these methodologies as it can support broader dissemination of information,33 safeguard anonymity, and reduce scheduling barriers during early stages of intervention development. This facilitates participant recruitment for testing.29 Integration of HPV vaccination within preexisting health services Multiple authors highlighted that HPV vaccination should be integrated into existing health services. Suggested entry points included LGBTQ health centers, sexual health clinics35,44 and local governmental and non-governmental organizations,36,40 with HIV testing or counseling services for MSM. In addition, support from healthcare providers, public health agencies, and community organizations was considered essential for actively promoting HPV vaccination within this population.39 Authors noted that such integration would be easier to scale up with minimal additional cost36 and could take advantage of preexisting data infrastructures that already support vaccination recording and monitoring.41,44 These services are also accustomed to working with individuals of diverse sexual orientations, making them well suited for reaching the target population.43 Evidence from the UK pilot program further indicated that incorporating HPV vaccination into sexual health services did not create a surge in demand, but nevertheless suggested that services may need additional resources to optimize vaccination initiation and completion.43 Structural factors are decisive for HPV vaccination adoption and reach Structural factors play a decisive role in shaping HPV vaccination adoption and overall reach. Policy and programmatic design elements such as the presence of school-based programs, the type of vaccine used, and procurement strategies can significantly influence both cost-effectiveness and reach.42 Additionally, system capacity matters and regions with fewer health resources and lower baseline vaccination rates require further study to better understand their context-specific barriers and needs.30 Access-related barriers also persist, particularly for older gay and bisexual men and individuals living with HIV, highlighting the need for expanded public funding for targeted programs or improved coverage through private insurance.39 Risk of bias and certainty assessment No articles were excluded during risk of bias assessment. Among quantitative papers (n = 16), there were low risks of bias related to temporal precedence, statistical validity, and reporting. Challenges were identified mainly within the areas of participant selection and allocation, and intervention delivery (Figure 2). For qualitative reports, we noted a need for greater transparency in reporting philosophical perspectives and researcher reflexivity. Figure 2.Summary of risk of bias assessment of quantitative studies, per area.X-axis: 0% to 100%, ticks at 20% intervals. Y-axis categories: comprehensiveness of reporting, temporal precedence, statistical conclusion validity, classification of exposure, assessment of outcome, confounding factors, participant retention, selection and allocation, administration of intervention. Legend: Yes, Unclear, No, N/A. Bars: comprehensiveness of reporting 100% Yes; temporal precedence 100% Yes; statistical conclusion validity 100% Yes; classification of exposure ~90% Yes, ~10% Unclear; assessment of outcome ~75% Yes, ~15% Unclear, ~2% No, ~8% N/A; confounding factors ~70% Yes, ~15% No, ~15% N/A; participant retention ~55% Yes, ~12% Unclear, ~13% No, ~20% N/A; selection and allocation ~50% Yes, ~35% Unclear, ~10% No, ~5% N/A; administration of intervention ~45% Yes, ~45% Unclear, ~10% N/A.A stacked horizontal bar graph showing risk of bias assessment results by study area. Summary of risk of bias assessment of quantitative studies, per area. Using the GRADE approach (Supplementary file 5), the overall certainty of evidence for both HPV vaccine initiation and series completion was rated as low. This was primarily due to study design, as many included studies employed non-randomized or quasi-experimental designs, as well as concerns regarding unclear randomization and blinding procedures in some RCTs. In addition, inconsistency was also noted, with considerable variation in effect estimates (odds ratios among RCTs and wide variation in vaccination uptake percentages reported in observational studies) across studies. Indirectness was generally low, as most studies directly assessed HPV vaccination outcomes among MSM populations. However, imprecision was a concern in several studies due to small sample sizes and wide confidence intervals. Additionally, the heterogeneity in outcome measures and reporting limited comparability across studies. Overall, these factors contributed to a low level of certainty in the evidence, suggesting that methodologically consistent and rigorous studies are needed to strengthen confidence in the observed effects Discussion This systematic review aimed to synthesize literature on interventions to increase HPV vaccine confidence and uptake among MSM and transgender persons. Among the 16 included articles, we identified eight distinct approaches. These efforts fell broadly into two categories: those focused on service providers and delivery, describing strategies to integrate HPV vaccination for MSM into existing health services; and those focused on service users, involving digital interventions designed to generate demand by increasing awareness, knowledge, and confidence related to HPV and the vaccine among MSM. Among the included studies, we identified some features associated with higher engagement in HPV vaccination interventions among MSM, as well as pragmatic approaches for integrating vaccination into existing services. Previous research has shown that although MSM generally express positive attitudes toward HPV vaccination, a persistent intention – behavior gap exists between willingness to vaccinate and actual vaccine uptake.9 Additionally, even in settings where HPV vaccination is offered, uptake has been reported to be suboptimal,10 indicating a need for additional and targeted support to translate positive attitudes into action. The studies included in this review suggest that multicomponent interventions, combining educational content about HPV with practical, actionable information delivered through digital platforms, are particularly engaging for MSM. These findings align with prior research identifying education and accessible information as key facilitators of vaccine uptake.45,46 Embedding such interventions within existing services frequently accessed by MSM, such as HIV or sexual health clinics,47 may represent an efficient approach that minimizes additional system burden. However, we found limited evidence on interventions to increase HPV vaccine uptake among MSM, with an even more pronounced lack of studies focusing on transgender populations. Globally, HPV vaccination research and programs have historically focused on the prevention of cervical cancer,48,49 contributing to a feminization of HPV-related disease prevention.21 While this focus may be justified given the burden of cervical cancer, a recent study suggests that social norms, e.g., the gendered representation of HPV vaccination and its strong association with cervical cancer, can result in avoidance of vaccination among transgender people.50 Moreover, HPV has been strongly associated with non-cervical cancers as well, including anal, penile, and oropharyngeal cancers, as well as anogenital warts, with particularly high prevalence observed among MSM and transgender people.6–8 The exclusion of these populations from early vaccination programs raises important equity concerns and underscores the need for more inclusive prevention strategies.51 In addition, the limited number of eligible studies demonstrated substantial heterogeneity. Differences in study designs, intervention components, delivery modes, and outcome measures, restricted our ability to compare interventions and assess their relative effectiveness. As a result, the current evidence base provides only limited guidance for the development and implementation of optimized, inclusive HPV vaccination strategies. Greater standardization in outcome measures and comparable study designs is needed to enable stronger evidence synthesis and support more actionable recommendations for policy and practice. While several countries continue to target girls only, most countries with the HPV vaccine included in their national vaccination programs have now adopted gender-neutral HPV vaccination policies.14,15 Over time, this will likely not only improve population-level protection in all genders but also show the most sustainable way to protect MSM and transgender persons. However, the current generation of post-adolescent MSM and people assigned male at birth will not benefit from gender-neutral routine vaccination programs and therefore requires timely, targeted interventions to reduce their ongoing risk. While some countries have begun implementing such targeted programs,19,38,42 their design and scale-up should be informed by robust evidence, evidence that is currently lacking. The paucity of studies in this area is not a new observation, especially for transgender populations,47,52 and this substantially limits our ability to answer the research question posed by this review for transgender people. Nevertheless, we interpret the minimal representation of transgender persons in the interventions described as suggesting a need not only for additional efforts to reach transgender populations, but also for their inclusion in the development of such interventions. Furthermore, no eligible studies were identified from low and middle-income settings (LMICs), further constraining policies for global and low resource settings. One possible reason for this is that the prevention of cervical cancer is prioritized as the most urgent health issue, particularly as the HPV vaccine is primarily available for adolescent girls only in many LMICs.53 However, the relative burden of other HPV-related cancers is expected to rise in the coming decades,54 highlighting the need for broader, equitable prevention efforts also outside of high-income countries. Still, without a robust evidence base, the meaningful inclusion of these populations in HPV vaccination policies remains difficult to achieve. Strengths and limitations To the best of our knowledge, this is the first study to systematically describe interventions and implementation strategies to improve HPV vaccine uptake among MSM and transgender people. Two authors independently conducted screening, risk of bias assessments, data extraction, and synthesis of all studies, contributing to the rigor of our findings. However, there are limitations to this work. Firstly, the decision to exclude gray literature in this review introduces the risk of publication bias as studies or interventions may have been overlooked. Similarly, all data collection in the included articles was conducted in the pre-pandemic era, meaning the review fails to capture potential attempts to leverage the systems established to facilitate prompt COVID-19 vaccinations. Thirdly, due to the small number of studies included and the substantial heterogeneity in study designs and outcomes, it was not possible to systematically incorporate the bias assessments into the synthesis and to conduct a meta-analysis to assess intervention effectiveness. While existing evidence demonstrates that HPV vaccination is effective among MSM47,55,56 and can be cost-effective when implemented in a timely manner,16–19 the variability in outcome measures across studies prevented meaningful quantitative synthesis. This lack of comparable effectiveness data hinders the identification of optimal intervention characteristics and limits guidance on how best to integrate vaccination strategies into existing health systems. Future studies should aim to align outcome measures with those used in existing literature to facilitate comparison and synthesis across studies. Future research and policy Assessing the characteristics of interventions that enhance engagement, alongside exploring the integration of HPV vaccination into preexisting services accessed by MSM, represents two pragmatic and complementary priorities for future research. In the past, several strategies have been proposed in the literature, including combining gender-neutral vaccination in preadolescence with selective vaccination of MSM.17,19 However, this approach depends on the existence of gender-neutral vaccination programs, which are not yet implemented in many regions, particularly in LMICs. The lack of evidence from LMICs limits the global applicability of our findings and risks hindering effective HPV prevention in these contexts, making this a priority area for future research. In such contexts, targeted vaccination of MSM may be the only feasible option, but to be cost-effective, these programs must be implemented promptly.19 Hence, these findings may be of relevance once targeted catch-up vaccination programs for MSM become available in LMIC setting. Understanding how to effectively design, implement, and scale selective vaccination strategies is therefore not only about improving HPV prevention among MSM today, but about reimagining systems that can ensure that even future vaccines e.g., HIV, reach populations too often left at the margins. Conclusion Improving HPV vaccine uptake among MSM and transgender people remains a priority to address health inequities and accelerate the eradication of HPV-related cancer. The findings of this systematic review offer some insights into how HPV vaccination programs targeting this group can be designed in an engaging, user-friendly, and accessible way without straining existing healthcare services. Embedding interventions and services into areas frequented by the end users, whether digital spaces or existing healthcare services, appears to be a promising strategy, providing a sense of safety and familiarity. Nevertheless, the exclusion of transgender persons underscores the urgent need for a more inclusive HPV prevention strategy. Supplementary Material Supplementary file 4.docx Supplementary file 1.docx Supplementary file 5.docx Supplementary file 3.docx Supplementary file 6.docx Supplementary file 2.docx